Artificial intelligence has been used to develop a next-generation vaccine that could protect against mutating viruses and ...
The Phase I trial, involving 39 healthy volunteers, tested the pEVAC-PS vaccine developed by Cambridge and its spin-out ...
Forbes contributors publish independent expert analyses and insights. Joshua Cohen is a Boston-based writer who covers health policy. While the media's attention has focused on unproven links between ...
As the Ebola epidemic raging in the Democratic Republic of the Congo shows no signs of abating, researchers around the world ...
Scientists have successfully tested an AI-designed universal coronavirus vaccine in humans for the first time, finding it to ...
Shionogi & Co. looks set to put its COVID-19 vaccine into practical use by the end of March 2022 following a government ...
The first human clinical trial of a universal Sarbeco coronavirus vaccine, developed by the University of Cambridge and ...
Since 2023, Moderna and Korea University have been developing a new mRNA vaccine for hantavirus. The work has been promising so far, but a finished product isn't likely coming any time soon.
Vaccine development for aquaculture species encompasses a diverse array of approaches designed to prevent bacterial, viral and parasitic diseases in farmed fish. Conventional strategies include ...
The 2025-2027 approval helps French innovators access Intravacc’s vaccine development, analytical development and cGMP manufacturing services ...
HIV prevention has come a long way—but the fight for a vaccine is far from over. In this op-ed, leaders in HIV advocacy and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results